Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Venlafaxine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 8/20 | 1.00 |
| ▸ | SLC6A4 known ✓ | P31645 | 8/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 0.97 |
| ▸ | CNR1 | P21554 | 1/20 | 0.97 |
| ▸ | HTR2A | P28223 | 1/20 | 0.97 |
| ▸ | HRH1 | P35367 | 1/20 | 0.97 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.97 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Venlafaxine SCHEMBL3863025 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3LMNACNR1 | |
| Venlafaxine SCHEMBL41936 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3LMNACNR1 | |
| (S)-Venlafaxine SCHEMBL4512264 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3LMNACNR1 | |
| Venlafaxine SCHEMBL3423495 | 0.99 | SLC6A2 (0.97) | SLC6A2SLC6A4SLC6A3LMNACNR1 | |
| Venlafaxine SCHEMBL7140489 | 0.99 | SLC6A2 (0.97) | SLC6A2SLC6A4SLC6A3LMNACNR1 | |
| (S)-Venlafaxine SCHEMBL3644633 | 0.99 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3LMNACNR1 | |
| Venlafaxine SCHEMBL60857 | 0.99 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3LMNACNR1 | |
| SCHEMBL10616028 | 0.99 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3LMNACNR1 | |
| Venlafaxine SCHEMBL1560692 | 0.99 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3LMNACNR1 | |
| SCHEMBL10614031 | 0.99 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3LMNACNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612210-B2 | Process for selective synthesis of enantiomers of substituted 1-(2-amino-1-phenyl-ethyl)-cyclohexanols | WYETH (US) | 2009-11-03 | — | — | US | disclosed |
| US-20090111818-A1 | Combinations of Eszopiclone and O-Desmethylvenlafaxine, and Methods of Treatment of Menopause and Mood, Anxiety, and Cognitive Disorders | SEPRACOR INC. (US) | 2009-04-30 | — | — | US | disclosed |
| EP-1680121-A4 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX INC (US) | 2007-12-26 | — | — | EP | disclosed |
| US-20070135449-A1 | Process for selective synthesis of enantiomers of substituted 1-(2-amino-1-phenyl-ethyl)-cyclohexanols | WYETH (US) | 2007-06-14 | — | — | US | disclosed |
| WO-2006136927-A1 | EXTENDED RELEASE FORMULATIONS COMPRISING VENLAFAXINE | GLENMARK PHARMACEUTICALS LIMITED (US) | 2006-12-28 | — | — | WO | disclosed |
| EP-1680121-A2 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | CombinatoRx, Incorporated (US) | 2006-07-19 | — | — | EP | disclosed |
| EP-1599212-A4 | COMBINATION THERAPY FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX INC (US) | 2006-02-08 | — | — | EP | disclosed |
| EP-1599212-A2 | COMBINATION THERAPY FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | Combinatorx, Incorporated (US) | 2005-11-30 | — | — | EP | disclosed |
| WO-2005037203-A2 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2005-04-28 | — | — | WO | disclosed |
| WO-2004073614-A2 | COMBINATION THERAPY FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2004-09-02 | — | — | WO | disclosed |
| US-20030190354-A1 | Extended release composition comprising as active compound venlafaxine hydrochloride | LYCORED LTD. (IL) | 2003-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111818-A1 | Combinations of Eszopiclone and O-Desmethylvenlafaxine, and Methods of Treatment of Menopause and Mood, Anxiety, and Cognitive Disorders | HTR4, HTR5A, CHRNA5 | SLC6A2 213/4885SLC6A4 55/4885SLC6A3 206/4885 |
| US-20070135449-A1 | Process for selective synthesis of enantiomers of substituted 1-(2-amino-1-phenyl-ethyl)-cyclohexanols | MAP2K4, MAP2K1, MAP2K6 | SLC6A2 3642/4885SLC6A4 3291/4885SLC6A3 2754/4885 |
| US-20030190354-A1 | Extended release composition comprising as active compound venlafaxine hydrochloride | SLC6A2, HTR5A, SLC6A4 | SLC6A2 1/4885SLC6A4 3/4885SLC6A3 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.